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Imaging probesa b s t r a c t
Tissue transglutaminase (transglutaminase 2) is a multifunctional enzyme with many interesting prop-
erties resulting in versatile roles in both physiology and pathophysiology. Herein, the particular involve-
ment of the enzyme in human diseases will be outlined with special emphasis on its role in cancer and in
tissue interactions with biomaterials. Despite recent progress in unraveling the different cellular func-
tions of transglutaminase 2, several questions remain. Transglutaminase 2 features in both conﬁrmed
and some still ambiguous roles within pathological conditions, raising interest in developing inhibitors
and imaging probes which target this enzyme. One important prerequisite for identifying and character-
izing such molecular tools are reliable assay methods to measure the enzymatic activity. This digest Let-
ter will provide clariﬁcation about the various assay methods described to date, accompanied by a
discussion of recent progress in the development of inhibitors and imaging probes targeting transgluta-
minase 2.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.TGase 2—Structure, basic functions and regulation: Tissue trans- tion, conformations, regulating factors/mechanisms and biochemi-
glutaminase (TGase 2) belongs to a family of enzymes (EC
2.3.2.13) that catalyze the Ca2+- and thiol-dependent posttransla-
tional modiﬁcation of proteins by the generation of isopeptide
bonds.1 These bonds are formed by an acyltransfer (transamida-
tion) reaction wherein a c-carboxamide group of a protein-bound
glutamine residue acts as an acyl donor and a wide spectrum of
primary amines act as acyl acceptors, especially protein-bound ly-
sine residues and low-molecular weight polyamines such as
putrescine, spermidine and spermine.1 In addition to transamida-
tion, TGases can also catalyze esteriﬁcation and hydrolysis reac-
tions of glutamine residues.2 Beside TGase 2, transglutaminase
activity has been observed for several other proteins, that is, factor
XIIIa (FXIIIa) of the blood clotting cascade and TGases 1, and 3–7.3
Within the transglutaminase family, TGase 2 is the most fre-
quently occurring member in eukaryotes and is present in almost
all mammalian cells. It is a unique enzyme whose cellular localiza-cal functions are in a complex interplay (Fig. 1). In addition to its
role as Ca2+-dependent catalyst of the aforementioned transamida-
tion reactions, TGase 2 is able to bind and hydrolyze GTP (and also
ATP). These diverse catalytic activities are structurally reﬂected in
a multidomain protein composed of four distinct domains (Fig. 2).
An N-terminal b-sandwich domain is followed by a central a/b-do-
main harboring the acyltransferase activity with Cys277, His335,
Asp358 and Trp241 as active site residues. This domain is con-
nected to two consecutive b-barrels located towards the C-termi-
nus. The two b-barrels, together with parts of the a/b
transamidase core domain, account for the GTPase activity of
TGase 2. The N-terminal b-sandwich does not contribute to catal-
ysis but confers afﬁnity to ﬁbronectin.4 Five calcium binding sites
have been identiﬁed in the a/b-domain, which cooperatively bind
up to six Ca2+ ions per molecule of protein.5 Through its GTPase
site, TGase 2 can act as a G protein (designated Gh) mediating
the signal transduction of a1-adrenergic- (a1B and a1D), oxytocin-
and thromboxane A2-receptors to the primary effector phospholi-
pase Cd.6 In this context, GTP/GDP and Ca2+ ions act as inverse
regulators of the GTPase and transamidase activities of TGase 2.
X-ray crystallographic investigations have shown that TGase 2
adopts a closed, transamidase-inactive conformation when GDP
is bound, in which the b-barrel domains interact noncovalently
with the a/b core domain (Fig. 2, left).7 Moreover, an X-ray
Figure 1. Representation of the complex interplay in TGase 2 physiology. TGase 2 in perinuclear recycling endosomes is depicted as . See text for further details.
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in complex with an irreversible inhibitor targeting the transami-
dase site.8 Within this complex, TGase 2 adopts an open conforma-
tion in which the transamidase domain is accessible for substrates
(Fig. 2, right). This conformational switch was conﬁrmed by elec-
trophoretic investigations via native polyacrylamide gel electro-
phoresis (nPAGE) and kinetic capillary electrophoresis. In these
experiments two different TGase 2 formswere observed, whose con-
centrations depend on the presence of Ca2+ ions, GDP and irrevers-
ible inhibitors.8,9 As well as the aforementioned transamidase and
GTPase activities, TGase 2 exhibits several additional biochemical
functions and has thus to be considered as a multifunctional protein.
As such, it can also act as a protein disulﬁde isomerase (PDI, Ca2+-
and GTP-independent),10 in which role it is probably responsible
for the correct folding of proteins constituting the mitochondrial
respiratory chain.11 TGase 2 can also act as a protein kinase with
insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) and ret-
inoblastoma protein (Rb) as conﬁrmed substrates.12 While these
enzymatic functions are widely accepted, the DNA nuclease activity
of TGase 2 suggested by Takeuchi et al. has yet to be conﬁrmed.13
The diverse catalytic activities are strictly regulated by different
mechanisms. As mentioned above, the transamidase activity of
TGase 2 is activated by Ca2+ ions and inhibited by GTP. A further
low-molecular weight factor that inﬂuences TGase 2 has been
identiﬁed as nitric oxide, which can abolish the transamidase
activity by Ca2+-dependent S-nitrosylation of multiple cysteineresidues.14 Additionally, TGase 2 can be inﬂuenced by posttransla-
tional modiﬁcations, among which regulation by disulﬁde forma-
tion is probably best understood.15 Disulﬁde bond formation in
TGase 2 does not involve active site Cys277 but three different cys-
teine residues, that is, cysteines 230, 370 and 371. Cys230 has been
shown to form an initial disulﬁde bond with Cys370 which under-
goes thiol-disulﬁde exchange with Cys371, resulting in a more sta-
ble vicinal disulﬁde.16 The oxidized, disulﬁde-bonded form of the
enzyme is acyltransferase-inactive and can be activated by thiore-
doxin.17 It has been found that TGase 2 can undergo phosphoryla-
tion at Ser216 (probably mediated by protein kinase A),18 which
inhibits the transamidase activity and mobilizes its protein kinase
activity.12b Potentially, TGase 2 can be regulated by N-acetylation
of lysine side chains, as the incubation with mild acetylating agents
attenuates its transamidase activity.19 Furthermore, regulation can
occur by limited proteolysis20 and interaction with phospholip-
ids.21 Beside these regulatory mechanisms, all of which act on
the protein level, TGase 2 can also be subject to transcriptional reg-
ulation. To this effect, TGase 2 does not only occur as full-length
enzyme but also in C-terminally truncated variants resulting from
alternative splicing of its primary transcript consisting of 13 exons.
These splice variants are referred to as TGase 2v1, TGase 2v2, tTGH
(also known as TGase-S) and tTGH2 with a length of 674, 645, 548,
and 349 amino acids, respectively, compared to 687 amino acids
for the full-length TGase 2. The truncation of the ﬁrst three splice
variants affects only the GTPase domain, resulting in altered
Figure 2. X-ray crystal structures of the closed (left) and open (right) conforma-
tions of human TGase 2 (hTGase 2) in complex with GDP and the peptidic inhibitor
Ac-P(DON)LPF–NH2 (DON: 6-diazo-5-oxo-L-norleucine), respectively. Fig. 2 was
prepared with PyMOL (DeLano, W. L. The PyMOL Molecular Graphics System. Version
1.5.0.3 Schrödinger, LLC) using the PDB ﬁles 1KV37 and 2Q3Z8, respectively.
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viewed in detail by Lai and Greenberg.22 In contrast, tTGH2 lacks
the GTPase domain completely and exhibits a C-terminally trun-
cated transamidase domain.22
Under physiological conditions, intracellular TGase 2 exists pre-
dominantly in its transamidase-inactive conformation, due to the
low intracellular Ca2+ concentration and the high energy load of
the cells.23 However, during situations of unbalanced Ca2+ homeo-
stasis, such as apoptosis or wound healing, TGase 2 undergoes ra-
pid activation upon binding of Ca2+ ions.23,24 This initiates
transamidation reactions in dying cells leading to the extensive
cross-linking of intracellular proteins, which stabilizes the dying
cell and thus prevents the release of harmful and immunogenic
degradation products.25 Although TGase 2 is predominantly a cyto-
solic protein, it also occurs in the nucleus, mitochondria as well as
in the extracellular matrix (ECM) and can be associated with pro-
teins of the cellular membrane (both inside and outside).26 Release
of TGase 2 into the extracellular matrix probably occurs by a non-
classical protein secretion pathway using perinuclear recycling
endosomes.27 In the extracellular environment, TGase 2 is mainly
transamidase-inactive despite the presence of Ca2+ and low levels
of GTP/GDP there.24,28 One reason for this—amongst others—is
probably the modiﬁcation of certain cysteine residues by disulﬁde
formation or nitrosylation reactions as mentioned before.14,16 Un-
der the inﬂuence of inﬂammatory stimuli, activation of extracellu-
lar TGase 2 can occur by thioredoxin-catalyzed reduction of the
disulﬁde bond between Cys370 and Cys371.17 Within the extracel-
lular matrix, the enzyme acts either as an adapter protein through
association with, for example, ﬁbronectin, integrins, and heparan
sulfates affecting cell adhesion, motility and cell survival or as a
transamidating enzyme stabilizing the extracellular matrix against
mechanic and proteolytic degradation.4a,28,29
TGase 2—Implications in human diseases: In the course of eluci-
dating the physiological roles of TGase 2, the involvement of thisenzyme in the pathogenesis of a number of diseases was revealed.
These include the autoimmune disorder celiac disease,30 neurode-
generative disorders, especially Alzheimer’s disease (AD), Parkin-
son’s disease (PD) and Huntington’s disease (HD),31 various kinds
of cancer32 and diseases related to tissue ﬁbrosis.33
Probably the best molecular description for the involvement of
TGase 2 in pathological disorders is established for celiac disease,
an autoimmune disease that is characterized by an impairment
of the small intestine.34 In the pathogenesis of this disorder, TGase
2 exerts two distinct functions. In the ﬁrst place, the enzyme
deamidates speciﬁc glutamine residues in the prolamin fraction
of gluten proteins, which results in increased binding afﬁnities of
these proteins to the human leukocyte antigen (HLA) serotypes
DQ2 and DQ8.35 Secondly, TGase 2 forms covalent complexes with
gluten, leading to activated T cells and ﬁnally to an immune re-
sponse against itself by generation of TGase 2 speciﬁc
autoantibodies.35b,36
The hallmarks of several neurodegenerative disorders are
extensive neuronal loss and progressive formation of insoluble
protein aggregates in the affected cerebral regions, called amyloid
plaques and Lewy bodies in the case of AD and PD, respectively.37 It
has been proven that both TGase 2 expression and its transamidase
activity are increased in the brains of persons suffering from these
neurodegenerative diseases.38 and citations therein Furthermore, the
corresponding disease-related proteins such as huntingtin, amy-
loid Ab, tau and a-synuclein are good substrates of TGase 2
in vitro.39 This indicates that TGase 2 may be signiﬁcantly involved
in the pathogenesis of neurodegenerative disorders, with recent re-
sults suggesting that TGase 2 catalyzes the formation of soluble
neurotoxic protein aggregates rather than insoluble
aggregates.38,40
Another pathological process related to protein aggregation is
cataractogenesis in the eye. There is accumulating evidence that
TGase 2 contributes to this process by cross-linking crystallins, that
is, the proteins constituting the eye lens, which consequently leads
to lens opaciﬁcation.41 Interestingly, this seems to correlate with
the formation of bis(c-glutamyl)spermidine cross-links between
the crystallin proteins. Increased spermidine concentrations were
found to prevent opaciﬁcation due to favoring the formation of sol-
uble protein-bound mono(c-glutamyl)spermidines.41c
Several studies have demonstrated that TGase 2 is overexpres-
sed in different kinds of cancer,42 including pancreatic carci-
noma,43 breast carcinoma44 and malignant melanoma.45 In this
context, elevated levels of TGase 2 in cancer cells have been asso-
ciated with increased drug resistance and metastasis.43–46 There is
evidence that TGase 2 mediates these properties by inﬂuencing the
focal adhesion kinase (FAK)/phosphoinositid-3-kinase/AKT-signal-
ing pathway activating FAK and inhibiting the phosphatase and
tensin homolog (PTEN), among other pathways.43,47 Furthermore,
TGase 2 causes activation of the nuclear factor jB (NF-jB) by a
variety of mechanisms.48 The most well conﬁrmed one of these
mechanisms seems to be the TGase 2-catalyzed polymerization
of the inhibitor of NF-jB a protein (IjBa) by intermolecular gluta-
mine-lysine cross-links.48a,b,f In addition to this, alternative mech-
anisms for NF-jB activation that do not require the transamidase
acitvity of TGase 2 have been discussed.48c,e,f On the other hand,
TGase 2 itself is subject to transcriptional control by NF-jB, which
leads to a self-stimulating signaling loop.48f The close relationship
between NF-jB and TGase 2 makes this enzyme a potential target
for inhibition. Such inhibition could potentially reverse chemo-
and radioresistance, as NF-jB is induced by genotoxic stress
elicited by alkylating and intercalating cytostatic agents, DNA anti-
metabolites, reactive oxygen species and ionizing radiation.43,49 A
further signaling pathway, involving TGase 2 leading to enhanced
cell growth has been revealed by Li et al., who demonstrated
that activation of the epidermal growth factor receptor (EGFR)
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the formation of a ternary complex between TGase 2, keratin-19
and the protein tyrosine kinase Src. The ternary complex, where
keratin-19 is presumably connected to TGase 2 as thioester with
Cys277, renders Src active conferring increased oncogenic poten-
tial to SKBR3 tumor cells.50 Furthermore, signaling between TGase
2 and EGFR seems to also work in the reverse direction, as it has
been recently shown that the enzyme can enlarge the lifespan of
EGFR in glioblastoma cells by preventing the ubiquitylation of
the intracellular receptor domains through complex formation
with c-Cbl, that is, an E3 ubiquitin ligase. In this process, the ability
of complex formation with c-Cbl has been attributed to the GTP-
bound, closed form of TGase 2.51
Not only intracellular signaling pathways, but also communica-
tion with other neoplastic and tumor-associated cells and inﬂu-
ences from the microenvironment shape tumor growth. TGase 2
has been shown to participate in these processes. In this context,
Wang and Grifﬁn recently found a correlation between TGase 2
and S100A4, another Ca2+ binding intra- and extracellular protein
which is also highly expressed in metastatic tumor cells and linked
with tumor progression.52 Their detailed investigations revealed
that S100A4 is a substrate for TGase 2-catalyzed transamidation
and that the cross-linking of S100A4 is involved in the activation
of the syndecan-4 and a5b1 integrin co-signaling pathway medi-
ated by protein kinase Ca (PKCa), which results in increased cell
migration. In addition to discrete molecules, tumor cells can also
release specialized extracellular organelles called microvesicles,
also known as exosomes or oncosomes, in order to promote tumor
development. Their cargo contains proteins and RNA which, when
taken up by neighbouring normal cells, can alter the phenotype of
these cells leading to enhanced cell survival and aberrant cell
growth.53 It has been demonstrated that TGase 2 plays an impor-
tant role in the transformation of ﬁbroblasts by microvesicles de-
rived from MDA-MB-231 and U87 tumor cells due to catalyzing
the formation of covalently linked ﬁbronectin dimers.54 Overall,
the TGase 2 induced changes can lead, via different signaling path-
ways, to epithelial–mesenchymal transition (EMT), where immo-
tile epithelial cells are transformed into motile mesenchymal
cells.46b,49e,55 Interestingly, a recent study showed that elevated
TGase 2 levels in A5489 lung cancer cells induce the expression
of N-cadherin, that is, a mesenchymal marker, to promote EMT.55c
Despite the widely described positive correlation of TGase 2
overexpression with tumor progression, some evidence has also
indicated that TGase 2 can have an inhibitory effect in certain can-
cers. It has been demonstrated that TGase 2 expression and trans-
amidase activity is reduced in primary tumors and the surrounding
stroma, allowing them to grow and to spread to distant sites.56 and
citations therein This is presumably linked to the functions of TGase 2
with regards to cell adhesion, motility and ECM stability. It has
been shown that TGase 2 in the extracellular space can activate
the G-protein coupled orphan receptor GPR56 via its C-terminal
b-barrel domains, which led to attenuation of metastasis in mela-
noma57 even though TGase 2 is not the only ligand for this recep-
tor.58 This may explain, in part, the antitumor effects of the
enzyme. Moreover, Jones et al. observed decreased tumor growth
and sometimes even tumor regression upon injection of TGase 2
into CT26 colon carcinoma-bearing mice.59 A recent study con-
ﬁrmed that reduced TGase 2 expression in CT26 colon carcinoma
occurs during tumor growth and progression.60 In addition to its
extracellular effects, a possible intracellular role of the transami-
dase activity of TGase 2 in regulating the metastatic potential has
been demonstrated where protein-linked c-glutamyl-polyamine
modiﬁcations in B16 melanoma cells were compared in cells which
had either high or low metastatic potential.61 The ﬁndings of this
study led the authors to hypothesize that a low transamidase activ-
ity and a concomitantly high content of intra- and extracellularpolyamines results in the preferential formation of mono(c-glut-
amyl) derivatives of polyamines, which correlates with a highly
metastatic phenotype. This directly maintains cellular plasticity
and ﬁnally favors cellular motility linked to metastasis.61,62 In this
regard, it is worth mentioning that it was recently established that
TGase 2 can mediate aminoalkylation of distinct Gln residues in ax-
onal tubulin, resulting in stabilization of microtubules, again sug-
gesting a link between the enzyme and cell motility.63
In summary, there is emerging evidence that TGase 2 is impli-
cated in tumor progression. However, the particular roles of TGase
2 and the importance of its transamidase activity in carcinoma
seems to depend on the tumor stage and cancer type, probably
resulting from the plethora of binding partners and substrates for
this enzyme, together with its different intra- and extracelluar
localizations and splice variants. Further investigations will ac-
count for a more detailed understanding of the functions of TGase
2 in cancer.56,62a
TGase 2 as important mediator of biomaterial–tissue interactions:
Based on its roles in the extracellular environment, another inter-
esting research ﬁeld for TGase 2 arises due to its participation in
processes of tissue response to polymeric biomaterials.64 In this re-
gard, a number of groups have demonstrated that the crosslinking
and macromolecule grafting function of TGase 2 can be applied as
an exciting tool to generate crosslinked biomaterials with im-
proved mechanical strength, resistance to proteolytic digestion,
and biocompatibility.65 On the other hand, studies on such bioma-
terials highlighted the importance of the adhesive properties of
TGase 2 that are independent of its ‘classical’ crosslinking func-
tion.66 This transamidase activity-independent promotion of cell
adhesion by TGase 2 was ﬁrst observed using plastic surfaces
coated with native and catalytically inactive TGase 2.67 TGase 2,
when in complex with ﬁbronectin, can enhance the attachment,
spreading, viability and proliferation of cells in contact with, or
migrating into, biomaterials. This, in consequence, stabilizes the
implant-tissue interface and can also improve biocompatibility.68
These effects are mediated by cell surface proteins like b1 inte-
grins.67 Additionally, the involvement of cell surface heparan sul-
fate proteoglycans has been demonstrated.69 Human osteoblasts
show increased cell spreading on poly(e-caprolactone) when the
polymer is coated with TGase 2/ﬁbronectin compared to either un-
coated or ﬁbronectin coated materials.70 The TGase 2/ﬁbronectin
complex binds to cell surface heparan sulfate proteoglycans such
as syndecan-4 which is synthesized by osteoblasts.71 Recently,
two studies investigating the heparan sulfate-binding site on
TGase 2 conﬁrmed the importance of matrix-bound TGase 2-synd-
ecan-4 interactions in cell adhesion.72 Moreover, a newmechanism
for rapid translocation of TGase 2 into the extracellular matrix,
which involves syndecan shedding, was proposed.72a Other cells
important in tissue regeneration like endothelial cells, smooth
muscle cells, and ﬁbroblasts also show improved attachment,
spreading, and survival on synthetic degradable biomaterials in
the presence of TGase 2/ﬁbronectin. Such polymeric materials in-
clude poly(e-caprolactone), poly(L-lactide), and poly(D,L-lactide-
co-glycolide).66,73 Future regenerative medicine will beneﬁt from
the development of comparatively simple biomaterials with
extrinsic physicochemical information, which are able both to
mobilize endogenous cells and to guide their development, sup-
porting tissue reorganization. This approach will avoid the difﬁcul-
ties associated with culture, storage, and distribution of
transplanted cells not to mention immune considerations. In this
regard, a current challenge is to understand the exact role of TGase
2 in recruitment of endogenous cells into polymer ﬁlms, scaffolds
or particles with appropriate architecture. Furthermore, under-
standing the mechanisms by which TGase 2 supports subsequent
tissue organization, for example, cell adhesion, differentiation,
and vascularization will offer various therapeutic possibilities to
Table 1
Kinetic parameters of substrates (Km, kcat and kcat/Km) obtained in assays with human FXIII activated by thrombin
Entry Acyl donora Acyl acceptora Km (M) kcat (s1) kcat/Km (M1 s1) Refs.
1 c-Chain of ﬁbrin 6.2  106 31.2 5,000,000 87ab
2 H-TIGEGQQHHLGGAKQAGDV-OH — — 500 87ab
3 H-GQQHHLGGAKQAGDV-OHc Biotin-H6Q15R5-OH 3.5  106 0.18 50,200 111bc
4 H-LGGAKQAGDV-OHc Biotin-H6Q15R5-OH 4.4  106 0.14 31,800 111bc
5 H-LTIGEGQQHHLGG-OH [14C]Dns-Cad 3.5  103 1.55 443d 91de
6 c-Chain of ﬁbrin [14C]Dns-Cad 4.1  105 0.36 8780d 91de
7 aS1-Casein [14C]Dns-Cad 6.8  105 0.087 1280d 91de
8 c1-Casein [14C]Dns-Cad 2.0  105 1.75 87,500d 91de
9 j-Casein [14C]Dns-Cad 9.2  105 0.26 2830d 91de
10 b-Casein [14C]Dns-Cad 3.1  105 1.63 52,600d 91de
11 b-Casein H-G-OEt 4.1  105 16.1 394,000 80cf
12 H-LGPGQSKVIG-OH H-G-OEt 1.4  103 78.0 54,400 80cf
13 H-NQEQVSPLTLLKLGN-OHg H-G-OEt 4.6  104 175 382,000 80cf
14 H-NQEQVSPLTLLK-OHg H-G-OEt 5.3  104 389 734,000 80af
15 Abz-NE(Cad-Dnp)EQVSPLTLLK-OHg H-G-OMe 2.0  105 — — 123ah
16 H-YE(pNA)KKVIG-NH2 H2O 6.5  105 0.15 2340 119bi
17 H-YE(pNA)VKVIG-NH2 H2O 4.4  105 0.17 3530 119bi
18 H-YE(pNA)IKVIG-NH2 H2O 7.4  105 0.17 2320 119bi
19 H-YE(pNA)LKVIG-NH2 H2O 5.8  105 0.12 2010 119bi
20 H-FE(pNA)VKVIG-NH2 H2O 7.4  105 0.12 1640 119bi
21 H-YE(pNA)VKVI-NH2 H2O 9.5  105 0.20 2060 119bi
22 H-YE(pNA)VRVIG-NH2 H2O 7.2  105 0.16 2250 119bi
23 H-YE(AMC)KKVIG-NH2 H2O 6.3  105 0.00124 19.7 121j
24 H-YE(AMC)VKVIG-NH2 H2O 3.9  105 0.00103 26.4 121j
25 H-YE(AMC)IKVIG-NH2 H2O 3.5  105 0.00118 33.7 121j
26 H-YE(AMC)VKVI-NH2 H2O 9.0  105 0.00213 23.7 121j
27 H-YE(AMC)VRVIG-NH2 H2O 7.5  105 0.00146 19.5 121j
28 H-K(N-Me-Abz)E(Put-Dnp)VKVIG-NH2 H2O 2.9  106 0.0235 8010 121h
29 H-YE(Put-Dnp)K(N-Me-Abz)KVIG-NH2 H2O 3.7  106 0.0177 4820 121h
a Kinetic parameters of acyl donor/acceptor substrates in bold letters.
b Kinetic parameters for the crosslinking of the c-chain of ﬁbrin or c-chain peptide H-TIGEGQQHHLGGAKQAGDV-OH were obtained by reduced SDS–PAGE and
densitometry.
c Oregon Green-labeled; measurement of plate-bound ﬂuorescence (kex = 485 nm, kem = 538 nm) in streptavidin-precoated microplates.
d Calculated from kcat and Km given.
e Measurement of protein-/peptide-incorporated radioactivity.
f Measurement of NADH depletion at k = 340 nm using the GDH assay (Scheme 1).
g Peptide derived from the N-terminal sequence of a2-plasmin inhibitor.
h FRET system: time-dependent increase in ﬂuorescence of Abz (kex = 313 nm, kem = 418 nm, Scheme 7) or N-Me-Abz (kex = 355 nm, kem = 460 nm) due to release of the
quenchers Dnp-Cad and Dnp-Put was measured, respectively. Put: putrescine.
i Time-dependent release of p-nitroaniline (pNA) was measured as increase in absorbance at k = 405 nm.
j Time-dependent release of 7-amino-4-methylcoumarin (AMC) was measured as increase in ﬂuorescence at kex = 380 nm, kem = 460 nm.
6532 M. Pietsch et al. / Bioorg. Med. Chem. Lett. 23 (2013) 6528–6543stimulate wound healing and tissue regeneration during the re-
sponse to artiﬁcial biocompatible and biodegradable poly-
mers.26a,74 Therefore, imaging of this enzyme in vivo using
selective probes is desirable.
Activity assays for TGases: In the past decades, several assay
methods have been developed to measure and quantify TGase
activity. As outlined above, TGase activity is exhibited by a further
seven isoforms, in addition to TGase 2. Most assay methods are de-
scribed for FXIIIa and TGase 2 and these will be covered in this sec-
tion. Due to the same type of reaction being catalyzed by different
TGases, the assays are applicable in principle to several isoforms.76
A variety of these methods are compatible with high-throughput
screening and these techniques have been applied for inhibitor
identiﬁcation and characterization (see Table 3 and text below).
TGase activity follows a ping–pong type mechanism, which in-
cludes the reversible acylation of an active-site cysteine residue
(Cys277) and release of one equivalent of ammonia (in the case
of a primary amide acting as acyl donor substrate, such as gluta-
mine) prior to deacylation by hydrolysis or aminolysis
(Fig. 3).75,77 Above pH 7 aminolysis is kinetically favored over
hydrolysis, while hydrolysis becomes more important at pHs be-
low 7.78 Both the acyl donor and acyl acceptor substrates, as well
as products formed in the transamidation reaction, have been used
to quantify the enzymatic activity. Kinetic parameters for selected
substrates of human FXIIIa and guinea pig TGase 2, that is, the
Michaelis constant, Km, the ﬁrst order catalytic rate constant, kcat,and the apparent second order rate constant kcat/Km, are summa-
rized in Tables 1 and 2.
a) Assays for determining the product ammonia: One of the
best established TGase assay strategies is a glutamate dehydroge-
nase (GDH)-coupled method (Scheme 1) allowing for the continu-
ous monitoring of TGase-catalyzed release of ammonia.77,79 This
assay is applicable if either or both the acyl-acceptor and acyl do-
nor substrate are proteins or small molecules/oligopeptides (Ta-
ble 1, entries 11–14; Table 2, entries 1, 2, 6, 7, 9, 10).77,80
Addition of GDH, a-ketoglutarate and either NADH77 or NADPH79
to the TGase assay mixture results in a decrease in absorbance at
340 nm, due to the oxidation of NAD(P)H to NAD(P)+. Kárpáti
et al.80a increased the sensitivity of the coupled assay for quantiﬁ-
cation of FXIIIa activity by exchanging NADPH for NADH, introduc-
ing the dodecapeptide H-NQEQVSPLTLLK-OH derived from the
N-terminal sequence of a2-plasmin inhibitor as new acyl donor
substrate, optimizing the concentration of assay components and
using an appropriate blank sample (Table 1, entry 14). Further
assay optimization was done by Kappel et al.,81 who applied
thio-NADH (Scheme 1) as the GDH substrate, allowing for detec-
tion of FXIIIa activity at 405 nm with a concomitant increase in
trueness of measurement and assay robustness compared to the
NADH-based methods. In order to obtain reliable results in the
GDH-coupled assay, enzyme amounts have to be adjusted in a
way that ensures the TGase reaction to be rate-limiting ([TGa-
se] << [GDH]). Furthermore, it is necessary to prove that neither
Figure 3. Schematic representation of the mechanism of TGase 2 transamidase activity. Acyl transfer to water and alcohols obeys a similar mechanism. Residue numbering
corresponds to the human enzyme. Created according to a scheme of Iismaa et al.75
M. Pietsch et al. / Bioorg. Med. Chem. Lett. 23 (2013) 6528–6543 6533substrates nor products of one enzyme interfere with the activity
of the other enzyme, and that GDH is no substrate of the TGase.77
GDH-coupled TGase assays have been developed for the accurate
quantiﬁcation of FXIIIa activity in plasma samples, which is neces-
sary before and during replacement therapy of patients suffering
from low FXIIIa plasma levels.80a,81 Moreover, as the GDH-coupled
method is applicable to a wide range of acyl donor and acyl accep-
tor substrates, provided that the former contains a primary amide
group, it represents a useful tool for general TGase kinetic studies,
including characterization of substrates77,80c and inhibitors (Ta-
ble 3, entry 1).80b,82 However, as this assay is rather insensitive
(TGase concentrations often used in inhibition assays are in the
high nanomolar range),80b,83 it is not suitable to investigate highly
potent inhibitors.82d Although the GDH-coupled assay is frequently
encountered in the literature, the majority of techniques for
monitoring TGase activity are based on other detection methods.
Another assay strategy described by Flanagan and FitzGerald84
uses o-phthaldialdehyde (OPA) for the discontinuous quantiﬁca-
tion of ammonia release during TGase-catalyzed cross-linking of
sodium caseinate. Here, the formed ammonia is spectrophotomet-
rically quantiﬁed in the supernatant at 340 nm after protein pre-
cipitation with trichloroacetic acid (TCA). Alternatively, a strategy
which has become the preferred method for determining the de-
gree of cross-linkage in food proteins catalyzed by microbial TGas-es85 was developed by Church et al.86 and involves the OPA reagent
being used to determine protein cross-linking, by following the de-
crease of OPA-reactive protein-bound amino groups. However, this
method is claimed to be less feasible than that of Flanagan and
Fitzgerald ‘due to the potential concealment of amino groups with-
in cross-linked sodium caseinate’.84
b) Assays using proteins as both acyl donor and acyl acceptor
substrates: A range of discontinuous assay strategies have been
developed to monitor the TGase-catalyzed cross-linking of pro-
teins, that is, by sodium dodecylsulfate polyacrylamide gel electro-
phoresis (SDS–PAGE, Table 1, entry 1),87 ion exchange
chromatography (quantiﬁcation of the cross-linking level),88 and
an enzyme-linked immunosorbent assay (ELISA)-like procedure.88b
The cross-linking of proteins has been used to investigate the
kinetics of the reaction of FXIIIa with the ﬁbrin c-chain87a and to
develop a transglutaminase activity staining for histological tissue
sections, using His6-Xpress-tagged green ﬂuorescent protein (GFP)
as a substrate.87b
In order to design new peptidyl linkers for the site-speciﬁc
enzymatic conjugation of functional proteins, the substrate speci-
ﬁcity of microbial TGases has recently been investigated with
two ﬂuorescence resonance energy transfer (FRET)-based strate-
gies on ﬂuorescent model proteins. On the one hand, the increase
in ﬂuorescence of the FRET acceptor protein is (continuously) fol-
Table 2
Kinetic parameters of substrates (Km, kcat and kcat/Km) obtained in assays with guinea pig TGase
Entry Acyl donora Acyl acceptora Km (M) kcat (s1) kcat /Km (M1 s1) Refs.
1 N,N-Dimethylcasein 3.3  106 0.14 44,000 80bb
2 N,N-Dimethylcasein H-G-OMe 1.6  106 0.16 97,000 80bb
3 N,N-Dimethylcasein Dns-Cad 2.3  106 0.14 64,000 80bc
4 N,N-Dimethylcasein Boc-K-NH(CH2)2NH-Dns 1.5  106 0.095 65,000 101c
5 Cbz-QG-OH HONH2 6.7  102 48.8 728 91a,105bd
6 Cbz-QG-OH Ac-K-OMe 9.6  103 2.80 292e 77b
7 Cbz-QG-OH CH3NH2 1.3  102 3.07 236e 77b
8 Cbz-QG-OH DMPDA 5  103 1 200e 115bf,g
9 Cbz-QG-OH H2O 1.8  103 0.17 96 80bb
10 Cbz-QG-OH H-G-OMe 1.4  103 0.16 110 80bb
11 Cbz-QG-Cad-Dns CH3(CH2)3NH2 9  104 —h — 112ai,j
12 Cbz-L-E(ONp)G-OH H2O 8.7  106 0.83 95,400e 118ak
13 Cbz-D-E(ONp)G-OH H2O 2.5  104 0.91 3640e 118ak
14 Cbz-G-cAbu-OCou H2O 9.0  106 1.25 139,000e 120al
15 Cbz-F-cAbu-OCou H2O 7.0  106 0.75 107,000e 120al
16 Cbz-F-cAbu-OCou NCCH2NH2 2.5  105 2.23 89,200e 120al
17 Cbz-F-cAbu-OCou Ac-K-OMe 1.5  105 1.85 123,000e 120al
18 Casein Biotin-TVQQEL-OH 1  106 — — 93cm
19 N,N-Dimethylcasein Biotin-Cad 5.3  105 — — 97an
20 N,N-Dimethylcasein Dns-Cad 1.4  105 — — 99o
21 5-Fam-HQSYVDPWMLDH-OH BSA 3.7  106 — — 104p,q
22 (b-Phenylpropionyl)thiocholine Dns-Cad 3  107r 0.8 2,670,000e 91cs
23 (b-Phenylpropionyl)thiocholine Dns-thia-Cad 7  107r 0.8 1,140,000e 91cs
24 Cbz-QG-OH DMPDA 2.5  104 — — 115ag
25 Cbz-QG-Cad-Dns CH3(CH2)3NH2 9.9  104 5.52 5570 112ai,j
26 Cbz-F-cAbu-OCou NCCH2NH2 1.6  105 1.23 76,900e 120al
27 Cbz-L-E(ONp)G-OHt NCCH2NH2 9.8  105 1.9 19,100 118bk
28 Cbz-F-cAbu-OCou Ac-K-OMe 1.5  103 1.6 1070e 120al
29 Cbz-L-E(ONp)G-OHt Ac-K-OMe 2.8  103 0.47 167 118bk
30 Cbz-G-OCou H-G-NH2 7.0  103 0.67 95.7e 120bl
31 Cbz-L-E(ONp)G-OHt H-G-NH2 4.7  103 1.75 373 118bk
a Kinetic parameters of acyl donor/acceptor substrates in bold letters.
b Measurement of NADH depletion at k = 340 nm using the GDH assay (Scheme 1).
c Increase in ﬂuorescence due to crosslinking of Dns-Cad (Scheme 2, kex = 330 nm, kem = 500 nm) and Boc-K-NH(CH2)2NH-Dns (kex = 330 nm, kem = 530 nm) with N,N-
dimethylcasein was measured, respectively.
d Quantiﬁcation of formed hydroxamate by measurement of absorbance at k = 525 nm after addition of FeCl3-TCA reagent.105a
e Calculated from kcat and Km given.
f His6-gpTGase.
g Time-dependent product formation (Cbz-E(DMPDA)G-OH, Scheme 5) was measured as increase in absorbance at k = 278 nm.
h Vmax = 8.4 lmol min1 mg1.
i TGase from bacterium Streptoverticillium mobaraense.
j HPLC-based assay. Product formation was monitored by measurement of both absorbance at k = 280 nm and ﬂuorescence at kex = 330 nm, kem = 520 nm.
k Time-dependent release of p-nitrophenol (HONp) was measured as increase in absorbance at k = 400 nm (Scheme 6).
l Time-dependent release of 7-hydroxycoumarin (HOCou) was measured as increase in ﬂuorescence at kex = 330 nm, kem = 460 nm (Scheme 6). cAbu: c-aminobutyric acid.
m Crosslinking of Biotin-TVQQEL-OH with casein was quantiﬁed using ExtrAvidin-peroxidase, H2O2 and tetramethylbenzidine (TMB). After stopping the peroxidase reaction
with H2SO4, absorbance was measured at k = 450 nm.
n Crosslinking of Biotin-Cad with N,N-dimethylcasein was quantiﬁed with streptavidin-b-galactosidase and p-nitrophenyl-b-galactopyranoside. p-Nitrophenol formation
was quantiﬁed at k = 405 nm.
o Fluorescence of Dns-Cad (Scheme 2, kex = 340 nm, kem = 535 nm) crosslinked to N,N-dimethylcasein was measured.
p Recombinant hTGase 2.
q Time-dependent crosslinking of 5-Fam-HQSYVDPWMLDH-OH to BSA was measured as increase in ﬂuorescence anisotropy at kex = 485 nm, kem = 535 nm (Scheme 3).
r Km values were corrected for the ‘effective concentrations of unprotonated amine species’. Uncorrected Km values for Dns-Cad and Dns-thio-Cad were 3  104 M (kcat/
Km = 2670 M1 s1)e and 7  105 M (kcat/Km = 11,400 M1 s1)e, respectively.91c
s Measurement of ﬂuorescence (kex = 340 nm, kem = 460 nm) of the amide coupling products N-(b-phenylpropionyl)dansylcadaverine and N-(b-phenylpropionyl)dansyl-
thiacadaverine, respectively (Scheme 4).113b
t Kinetic parameters for hydrolysis of Cbz-L-E(ONp)G-OH: Km = 2.0  105 M; kcat = 0.28 s1, kcat/Km = 14,200 M1 s1.
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tagged ﬂuorescent protein pairs, such as enhanced blue ﬂuorescent
protein/enhanced GFP (eBFP/eGFP) and enhanced cyan ﬂuorescent
protein/enhanced yellow ﬂuorescent protein (eCFP/eYFP).89 On the
other hand, both in vitro and in vivo quenching assays have been
developed, monitoring the decrease of yellow ﬂuorescence of the
FRET donor protein eYFP (covalently attached to the acyl acceptor
substrate) when crosslinked to Discosoma sp. red ﬂuorescent pro-
tein (DsRed, covalently attached to the acyl donor substrate). In
this system, the ﬂuorescence of the FRET acceptor DsRed does
not signiﬁcantly increase due to the TGase-catalyzed reaction.90
c) Assays using a combination of proteins and small mole-
cules/oligopeptides as acyl donor and acyl acceptor substrates:
A large variety of discontinuous and continuous assays followsthe TGase-catalyzed incorporation of small molecules/oligopep-
tides into proteins by quantiﬁcation of the macromolecular prod-
uct. Discontinuous methods include the reaction of 14C- and 3H-
labeled primary amines (e.g., [14C]monodansylcadaverine
{[14C]Dns-Cad} and both [14C]- and [3H]putrescine) with various
types of casein and the measurement of the protein-bound radio-
activity after TCA precipitation (Table 1, entries 6–10).91 In the
past, these radiometric assays have often been used for the charac-
terization of TGase inhibitors (Table 3, entry 2),91a,92 and for the
quantiﬁcation of TGase activity in biological samples. The latter in-
cludes the measurement of FXIII activation in human plasma91e
and determination of TGase 2 activity in human brain samples of
patients suffering from Alzheimer’s disease (AD).91f Another assay
strategy monitors the incorporation of biotinylated glutamine- or
Table 3
TGase 2 assays used for the identiﬁcation and characterization of inhibitors
Entry Acyl donor Acyl acceptor Mode Refs.
1 Cbz-QG-OH H2O Continuous 82a
2 Casein [14C]- and [3H]putrescine Discontinuous 91a,92b
3 N,N-Dimethylcasein Biotin-Cad Discontinuous 95,96,126c
4 N,N-Dimethylcasein Dns-Cad Continuous 102a–c,102hd
5 N,N-Dimethylcasein Boc-K-NH(CH2)2NH-Dns Continuous 95,102d–ge
6 Cbz-QG-OH HONH2 Discontinuous 105b,108,109f
7 Cbz-QG-OH DMPDA Continuous 116g
8 Cbz-E(ONp)G-OH H2O Continuous 127h
9 Cbz-F-cAbu-OCou H2O Continuous 82d,127ai
10 Dns-e-aminocaproyl-QQIV-OH Dnp-Cad Continuous 102hj
11 Abz-APE(Cad-Dnp)QEA-OH H-G-OMe Continuous 128k
a Measurement of NADH depletion at k = 340 nm using the GDH assay (Scheme 1).
b Scintillation counting of 3H incorporated into TCA-precipitated casein.
c Determination of the increase in absorbance at k = 405 nm due to nitrophenyl phosphate hydrolysis catalyzed by streptavidin-conjugated alkaline phosphatase.93a
d Increase in ﬂuorescence due to cross-linking of Dns-Cad (Scheme 2, kex = 360 nm, kem = 500 nm) with N,N-dimethylcasein was measured.102a
e Increase in ﬂuorescence due to cross-linking of Boc-K-NH(CH2)2NH-Dns (kex = 350 nm, kem = 535 nm) with N,N-dimethylcasein was measured.76
f Quantiﬁcation of formed hydroxamate by measurement of absorbance at k = 525 nm after addition of FeCl3-TCA reagent.105a
g Product formation (Cbz-E(DMPDA)G-OH, Scheme 5) was measured as increase in absorbance at k = 278 nm.115a
h Release of HONp was measured as increase in absorbance at k = 400 nm (Scheme 6).118b
i Release of HOCou was measured as increase in ﬂuorescence at kex = 330 nm, kem = 460 nm (Scheme 6).120a
j FRET system: decrease in ﬂuorescence due to quenching of Dns-e-aminocaproyl-QQIV-OH (kex = 360 nm, kem = 590 nm) by the quencher Dnp-Cad.129
k FRET system: time-dependent increase in ﬂuorescence of Abz (kex = 313 nm, kem = 418 nm) due to release of the quencher Dnp-Cad was measured.123b
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dium caseinate, N,N-dimethylcasein and ﬁbrinogen. For product
detection, colorimetric assays using avidin-/streptavidin-enzyme
conjugates (Table 2, entry 18)93 or ﬂuorophore-labeled streptavi-
din94 are applied. This assay strategy has often been used for
screening and characterization of TGase inhibitors (Table 3, entry
3)95,96 and was applied for the determination of FXIIIa in human
plasma93b and the simultaneous measurement of TGase 2 and
FXIIIa activities in human cell extracts.94 A similar method has
been employed to investigate in situ TGase activity after immobi-
lization of the biotinylated products (Table 2, entry 19) and to
study the cellular regulation of the enzyme.97
The application of discontinuous assay strategies to kinetic
analysis of enzymatic reactions requires sampling of the reaction
mixture at time intervals with both control of sample volume
and separation of substrate and product being absolutely neces-
sary. In contrast, continuous assay methods allow for a relatively
simple real-time measurement of enzyme activity.98 Some of these
continuous methods are based on an observation by Lorand
et al.,98a who found the TGase-catalyzed incorporation of Dns-
Cad into a-casein (Scheme 2) to result in a ‘shift in both the wave-
length (535 nm to 515 nm) and the intensity of ﬂuorescence of
the dansyl group’ due to placement of the ﬂuorophore in a more
hydrophobic environment (Table 2, entry 3).80b
The same principle is applied in the reaction of N,N-dimethylca-
sein with Boc-K-NH(CH2)2NH-Dns (Table 2, entry 4).101 Both meth-
ods have been extensively used in the search for inhibitors
(Table 3, entries 4 and 5).76,95,102 Another continuous assay
strategy utilizes the increase in ﬂuorescence anisotropy103 due to
incorporation of ﬂuorescent molecules, such as Dns-Cad100 (acyl
acceptor substrate, Scheme 2) or 5-carboxyﬂuorescein (5-Fam)-
labeled PepT26 (acyl donor substrate, Scheme 3; Table 2, entry
21)104 into Hammarsten casein and bovine serum albumin (BSA),
respectively. The latter method is particularly sensitive (picomolar
concentrations of TGase are detected) and can be easily adapted for
the high-throughput screening of TGase inhibitors.104
d) Assays using small molecules/oligopeptides as both acyl
donor and acyl acceptor substrates: Both discontinuous and con-
tinuous TGase assay methods have also been developed with low-
molecular weight compounds/oligopeptides as acyl donor and acyl
acceptor substrates. One of the earliest methods monitors the reac-tion between Cbz-QG-OH and hydroxylamine (Table 2, entry
5),91a,105 with the hydroxamate formed being spectrophotometri-
cally quantiﬁed after addition of FeCl3-TCA reagent106 and removal
of the precipitated protein.107 Although relatively insensitive (see
below, micromolar concentrations of TGase are used in the
assay),108 this method has been applied in the past for inhibitor
identiﬁcation (Table 3, entry 6).105b,108,109 Other discontinuous as-
say strategies include separation of substrate from product fol-
lowed by ELISA-like procedures110 or densitometric (Table 1,
entry 2),87a radiometric (Table 1, entry 5),91d and ﬂuorescence-
based (Table 1, entries 3 and 4)111 product detection, respectively.
Recently, two ﬂuorimetric HPLC-based techniques have been intro-
duced which monitor the coupling of Cbz-QG-OH to Dns-Cad and
that of Cbz-QG-Cad-Dns to unlabeled amines, such as butylamine
(Table 2, entries 11 and 25), with the latter one having been used
for the characterization of TGase acyl acceptor substrates and
TGase preparations.112
Continuous assay strategies with small molecules as substrates
often feature spectrophotometric, ﬂuorimetric or FRET-based read-
outs, which allows for the kinetic analysis of the enzymatic
reaction. An early method introduced by Lorand113 applies a two-
phase system (water/n-heptane) using (b-phenylpropionyl)-
thiocholine and Dns-Cad/dansylthiacadaverine (Dns-thia-Cad) as
water soluble acyl donor and acyl acceptor substrates, respectively
(Scheme 4, Table 2, entries 22 and 23).91c The hydrophobic cou-
pling products, that is, N-(b-phenylpropionyl)dansylcadaverine or
N-(b-phenylpropionyl)dansylthiacadaverine, are continuously ex-
tracted into the n-heptane phase and quantiﬁed by direct ﬂuores-
cence measurement.113b The same substrates have also been used
in an aqueous assay system, with the formation of the second
product, that is, thiocholine, being continuously determined with
Ellman’s reagent.114 Both methods were shown to give comparable
kinetic parameters Km and kcat for the two amine substrates.113b,114
Another homogenous assay monitors the product formation of the
reaction between Cbz-QG-OH and N,N-dimethyl-1,4-phenylenedi-
amine (DMPDA) (Scheme 5; Table 2, entries 8 and 24),115 and
has been used for characterization of some TGase inhibitors (Ta-
ble 3, entry 7).116 A ﬂuorescence-based strategy follows the trans-
amidation between Cbz-QG-Cad-Dns and Dns-Cad to give highly
ﬂuorescent Cbz-E(Cad-Dns)G-Cad-Dns.117 The two substrates of















































Scheme 1. Glutamate dehydrogenase (GDH)-coupled TGase assay. Ammonium produced by the TGase reaction is used for the GDH-catalyzed reductive amination of a-
ketoglutarate to L-glutamate.77,79
6536 M. Pietsch et al. / Bioorg. Med. Chem. Lett. 23 (2013) 6528–6543TGase, while p–p stacking of the two dansyl groups within the
product results in ﬂuorescence enhancement.91c,117
Another category of TGase assays monitor the hydrolysis/ami-
nolysis of chromogenic and ﬂuorogenic acyl donor substrates by
determining the release of the chromophores p-nitrophenol
(HONp, Scheme 6 and Table 2, entries 12, 13, 27, 29 and 31)118
and p-nitroaniline (pNA, Table 1, entries 16–22)119 or the ﬂuoro-
phores 7-hydroxycoumarin (HOCou, Scheme 6 and Table 2, entries
14–17, 26, 28, 30)120 and 7-amino-4-methylcoumarin (AMC, Ta-
ble 1, entries 23–27).121
Recently, application of small molecule substrates has been de-
scribed for FRET-based TGase assays. Gnaccarini et al.122 use a
strategy that follows the ligation-dependent decrease in ﬂuores-
cence of the FRET donor group (coumarin), upon excitation at
k = 405 nm, as the donor group ﬂuorescence is more pronounced
than the concomitant increase of the FRET acceptor ﬂuorescence
(ﬂuorescein). Similarly, decrease of Dns ﬂuorescence in Dns-e-
aminocaproyl-QQIV-OH occurs due to reaction with the quencher
Dnp-Cad (Table 3, entry 10).2b Other methods, in contrast, apply
internally quenched FRET systems as acyl donor substrates, such
as 2-(methylamino)benzoyl (N-Me-Abz)/dinitrophenyl (Dnp) (Ta-
ble 1, entries 28 and 29)121 and 2-aminobenzoyl (Abz)/Dnp
(Scheme 7; Table 1, entry 15 and Table 3, entry 11).123 Here, re-
lease of the quencher Dnp during the TGase-catalyzed transamida-
tion results in the increase of ﬂuorescence of N-Me-Abz and Abz,
respectively.121,123 As reﬂected by entries 8–11 in Table 3, the as-
say strategies outlined in the previous and present paragraphs
have been successfully employed for the identiﬁcation and kinetic
characterization of TGase inhibitors.
The various TGase assay methods described in the literature
have been shown to have their advantages and disadvantages.
The hydroxamate assay, using Cbz-QG-OH and hydroxylamine is
often applied to determine the speciﬁc activity of TGase. Although
fast and reproducible, this method is relatively insensitive as the
extinction coefﬁcient of the formed hydroxamate-Fe3+ complex is
relatively small (850 M1 cm1 at kmax = 525 nm) and thus com-
paratively large amounts of enzyme are required to obtain accurate
results.91a,107,112b,117,124 ELISA-like assay procedures are more sen-
sitive, but contain several steps for quantiﬁcation of enzyme activ-
ity.117 Radiometric and ﬂuorimetric assays remain the most
sensitive and accurate methods for determining TGase activ-
ity.110a,125 However, techniques using radioactively labeled sub-
strates require special facilities and are relatively timeconsuming, which limits their use for investigating large numbers
of compounds.88b,117,125 The different ﬂuorescent assays available
also have certain limitations. Separation of conjugated products
from ﬂuorescently-labeled reactants is a common problem
encountered with discontinuous assays, and may be necessary
for continuous methods, e.g., the method of Lorand et al.98a
(Scheme 2) monitors ‘relative ﬂuorescence enhancement’, as free
ﬂuorescent substrate molecules interfere with product ﬂuores-
cence.99,110a Another continuous ﬂuorimetric method introduced
by this group applies a two-phase system, by which ﬂuorescent
product and substrate are separated.113 Here, the nature of the as-
say prevents its use for high-throughput inhibitor screening.117
The assay by Jeitner et al.117 allows for the direct continuous ﬂuo-
rimetric determination of the TGase-mediated transamidation by
quantiﬁcation of the product Cbz-E(Cad-Dns)G-Cad-Dns.120a While
this assay is one of the most sensitive methods, it is very speciﬁc
for the two substrates used, that is, Cbz-QG-Cad-Dns and Dns-
Cad (see above). In contrast, ﬂuorogenic acyl donor substrates
releasing 7-hydroxycoumarin during acyl-enzyme formation
(Scheme 6) can be utilized for characterization of various acyl
acceptor substrates.120 These ﬂuorogenic acyl donor substrates
show minimal nonenzymatic hydrolysis and thus are more suit-
able than the similarly used chromogenic p-nitrophenyl esters,
such as Cbz-E(ONp)G-OH (Scheme 6).111a,118b,120a Although valu-
able tools, the applicability of such ﬂuorogenic substrates is limited
due to their poor solubility under assay conditions.120a In contrast,
ﬂuorogenic FXIIIa substrates releasing AMC (Table 1, entries 23–
27) are less suited for activity measurements than their corre-
sponding chromogenic pNA analogs (Table 1, entries 16–18, 21
and 22). Although having similar Km values, the AMC substrates
are hydrolyzed with kcat values that are two orders of magnitude
lower than those of the pNA derivatives, which has been attributed
to the bulkiness of the coumarin ring system.119b,121 A complemen-
tary assay strategy allowing for the characterization of acyl donor
substrates is the DMPDA method (Scheme 5), which monitors the
transamidase activity of TGase by spectrophotometric determina-
tion of the formed anilide.111a,115
The acyl donor/acyl acceptor pairs often employed for the
development of TGase 2 inhibitors are surveyed in Table 3. Contin-
uous assays are preferably applied for this purpose, with N,N-dim-
ethylcasein being the most abundantly used acyl donor substrate.
Recent developments toward TGase 2 inhibitors: As mentioned



















Scheme 2. TGase-catalyzed crosslinking of dansylcadaverin (Dns-Cad) to casein. Various detection methods for quantiﬁcation of the macromolecular product have recently
been applied, such as measurement of protein-bound Dns ﬂuorescence (Table 2, entry 20),99 increase in Dns ﬂuorescence,80b,98a and ﬂuorescence anisotropy100 or protein-




















Scheme 3. Fluorescence anisotropy-based TGase assay. Incorporation of 5-carboxyﬂuorescein (5-Fam)-labeled peptide ‘PepT26’ (sequence H-HQSYVDPWMLDH-OH) into
BSA is quantiﬁed as increase in ﬂuorescence anisotropy at kex = 485 nm, kem = 535 nm.104
M. Pietsch et al. / Bioorg. Med. Chem. Lett. 23 (2013) 6528–6543 6537the different enzymatic activities, the transamidase and GTPase
activities are the ones best conﬁrmed experimentally. As a result,
inhibitors for this enzyme can be categorized into those targeting
the transamidase or acyltransferase domain and those binding to
the GTPase domain. As compounds of the latter category mostly
represent analogs of GTP and GDP, which stabilize the closed,
transamidase-inactive conformation, they concomitantly act as
uncompetitive inhibitors of the transamidase domain. Inhibitors
that target the transamidase domain directly are very often sub-
strate analogs containing an electrophilic group (also referred to
as a ‘warhead’) which results in an irreversible covalent interaction
with the active-site thiol of Cys277. The classes of TGase 2 inhibit-
ing compounds have recently been reviewed in depth.39,130 More
recent publications of inhibitors describe compounds with an
acrylamide moiety as warhead, which were developed as thera-















Scheme 4. TGase-catalyzed amide formation between Dns-Cad/Dns-thia-Cad and (b-ph
crosslinked product in n-heptane and measurement of ﬂuorescence113b or by determina
acid)).114In one of these studies, a collection of 283,000 compounds was
screened resulting in four conﬁrmed hits. Out of these, N-4-bromo-
phenyl acrylamide was rated the most attractive lead structure.
Substitution of the bromine atom by a piperazine-1-sulfonyl moi-
ety enabled extensive structure–activity relationship (SAR) studies
by attaching various acyl residues to the piperazine-N4-atom.
Compound 1 was found to be the most potent TGase 2 inhibitor
of this series, based on the IC50 value displayed upon 30 min prein-
cubation of the compound with the enzyme monitored using the
ﬂuorimetric assay of Case et al. outlined above.76,101 The adamantyl
moiety of 1 is thought to interact with a lipophilic region deﬁned
by Phe316, Leu312, Ile331, and Leu420 (hTGase 2 numbering). This
binding pocket seems to be important for the selectivity over other
TGase isoforms, as it consists of more polar side chains within the
latter enzymes. The importance of the acrylamide and sulfonyl












enylpropionyl)thiocholine. TGase activity is quantiﬁed by continuous extraction of





























Scheme 5. TGase-catalyzed DMPDA assay, that is, coupling of Cbz-QG-OH with N,N-dimethyl-1,4-phenylenediamine (DMPDA). Formation of the anilide product Cbz-
E(DMPDA)G-OH is followed by measuring the absorbance at k = 278 nm.115a
6538 M. Pietsch et al. / Bioorg. Med. Chem. Lett. 23 (2013) 6528–6543limited selection of inhibitors, drug metabolism and pharmacoki-
netics (DMPK) proﬁling was performed examining the plasma pro-
tein binding, membrane permeability and plasma stability among
other parameters. The analysis revealed rather short half-lifes in
mouse plasma for this inhibitor type (248 min for compound 1),
which was attributed to hydrolytic cleavage of the acrylamide C–
N bond.102e Therefore, the aromatic and cycloaliphatic moieties
were inverted for the next generation of nonpeptidic acrylamide
inhibitors by attaching the acryloyl residue to 4-aminopiperidine
instead of aniline. Comprehensive investigation of SAR for the sub-
stituent at the 4-position of the benzenesulfonyl moiety resulted in
compound 2 (Table 4) which is ten times less potent at inhibiting
hTGase 2 than 1 but exhibits a considerably increased plasma
half-life.102f
SAR were also explored for a series of related compounds con-
sisting of Na-acyl-Ne-acryloyl-lysine-amides.102g The inhibitory
properties of this structural scaffold were earlier discovered by
Marrano et al.116b Attachment of a 4-arylpiperazinyl moiety to
the lysine carboxy group was revealed to be advantageous for
the inhibitory potency. The most potent compound of this series,
that is, compound 3 (Table 4), displayed an IC50 value as low as
14 nM together with an excellent selectivity proﬁle for hTGase 2
over other TGase isoforms. In addition, inhibitor 3 exhibited high
stability in mouse and human plasma with half-lifes of more than
24 h.102g
All acrylamides discussed have been found to undergo active


























Cbz-G-γAbu-OCou : R = H
Cbz-F-γAbu-OCou : R = CH2Ph
H2
Scheme 6. TGase-catalyzed hydrolysis/aminolysis of the chromogenic substrate Cbz-E(O
Product formation is quantiﬁed by measurement of p-nitrophenol absorbance (k = 400
kem = 460 nm),120a respectively.evaluated them to have limited suitability for targeting TGase 2
in CNS-related disorders.
Inhibitors bearing Michael acceptors are also the subject of a
patent, published in 2008 by Oertel.128 The glutamine residue of
peptidic substrates was replaced by a moiety derived from (S)-2-
amino-5-hexenoic acid containing electron-withdrawing substitu-
ents, such as alkoxycarbonyl and methylsulfonyl in 6-position. This
places the electrophilic site prone to nucleophilic attack by the
thiol group of Cys277 at exactly the same position as the side-chain
carbonyl of glutamine. The IC50 values of 54 compounds of this
type for inhibition of hTGase 2, hTGase 1 and FXIIIa are reported
and the three most potent inhibitors are shown in Table 5. Com-
pounds 4–6 display potent and selective inhibition of hTGase 2
over FXIIIa. X-ray crystal structures of hTGase 2 in complex with
the free carboxylic acids derived from the methyl esters 4 (3S3P)
and 5 (3S3S) have been solved and deposited in the Protein Data
Bank.131
Most recently, SAR have been published for dipeptide-based
reactive methyl ketones containing 2-mercaptoimidazolium leav-
ing groups (Fig. 4).126 Their inhibitory potencies are strongly
dependent on the substitution pattern of the imidazolium moie-
ties. Substituents at the nitrogen atoms that are more bulky than
a methyl group are not tolerated, but inhibitory potency was re-
tained when the methyl substituents at C4 and C5 were replaced
by propyl groups. Remarkably, these inhibitors lack selectivity be-
tween hTGase 2 and FXIIIa, whereas analogous dimethylsulfonium



























X = OH or NHR1
+
Np)G-OH and the ﬂuorogenic substrates Cbz-G-cAbu-OCou and Cbz-G-cAbu-OCou.















































Scheme 7. TGase-catalyzed transamidation between the FRET system Abz-NE(Cad-Dnp)EQVSPLTLLK-OH (peptide sequence derived from a2-antiplasmin) and H-G-OMe. The
increase in ﬂuorescence of the N-terminal 2-aminobenzoyl (Abz) due to release of the quenching 2,4-dinitrophenyl (Dnp) moiety is measured at kex = 313 nm,
kem = 418 nm.123a
Table 4



























Compound IC50 (nM) Refs.
hTGase 2 mTGase 2a hTGase 1 hTGase 3 FXIIIa hTGase 6
1 10 16 3400 >80,000 180 840 102e
2 110 55 1240 Not tested 6400 34,000 102f
3 14 Not available 15,000 >80,000 35,000 >80,000 102g
a mTGase 2, murine TGase 2.
Table 5
General structure and inhibitory potencies of Michael-acceptor based peptidic hTGase







Compound EWG Xaa IC50 (nM)
hTGase 2 FXIIIa hTGase 1
4 CO2CH2CH3 Gln 20 >50,000 n.d.a
5 CO2CH2CH3 Val 30 >50,000 n.d.a
6 SO2CH3 Gln 54 >100,000 250















X = H, R1 = R2 = R3 = R4 = CH3:
IC50(TGase 2) = 1 µM, IC50(FXIIIIa) = 2 µM
Qualitative SAR:
X: H ≈ benzyl
R1, R2: methyl > ethyl >
propyl > phenyl, benzyl
R3, R4: methyl ≈ propyl
Figure 4. General structure of dipeptide-derived reactive methyl ketones contain-
ing a 2-mercaptoimdazolium leaving group and qualitative SAR for inhibition of
hTGase 2 and FXIIIa.126
M. Pietsch et al. / Bioorg. Med. Chem. Lett. 23 (2013) 6528–6543 6539been explained on the basis of molecular modeling studies, which
suggest that the imidazolium moiety interacts with Trp241 and
Trp323, that is, residues that are present in both TGase 2 as well
as FXIIIa. In the case of dimethylsulfonium inhibitors, the confor-
mation around the reactive methylene group seems to differ fromthat in their imidazolium counterparts and favors cation-p interac-
tions between the sulfonium group and Phe325 of TGase 2. This
residue corresponds to Tyr372 in FXIIIa, which adopts a different
conformation that does not promote cation-p interactions.126
Molecular imaging of TGase 2: There are two distinctive ap-
proaches to imaging TGase 2 in biological objects. The ﬁrst cate-
gory deals with the visualization of the enzyme on its own,
based on the expression of recombinant TGase 2 fusion proteins
that are covalently linked to ﬂuorescent proteins. This approach
was used to monitor the conformational transition between the
closed and open form of the enzyme within its intracellular envi-
ronment by ﬂuorescence microscopy. For this purpose, hTGase 2
was conjugated with YFP and CFP at its N- and C-terminus, respec-



























































































Figure 5. Inhibitors used to induce conformational changes within TGase 2 inside living cells (compounds 7 and 8) and imaging probes to target TGase 2 in living objects
(compounds 9–13).
6540 M. Pietsch et al. / Bioorg. Med. Chem. Lett. 23 (2013) 6528–6543(distance 16 Å) results in FRET between CFP and YFP, which will be
interrupted upon transition to the open conformation as the dis-
tance increases to 140 Å. Pavlyukov et al. expressed this construct
in A549 and CHO cells as well as in mouse ﬁbroblasts by transfec-
tion with the coding plasmid. Microscopic FRET monitoring in
these cells revealed that a considerable amount of the enzyme is
located in the perinuclear recycling compartment and is present
in the form of closed, transamidase-inactive protein. Open, trans-
amidase-active TGase 2 was detected close to the outer cell mem-
brane. The transition of the conformation from close to open
triggered by ionophore-mediated Ca2+ inﬂux, and staurosporine-
mediated apoptosis has been monitored using this FRET-based
approach.132a In a similar study, Caron et al., revealed that the irre-
versible acrylamide-based inhibitor 7 (Fig. 5) induces the confor-
mational transition to the open form in STHdh cells. In contrast,
the cinnamoyl triazole 8 (Fig. 5) targeting the transamidase do-
main in a reversible manner stabilizes TGase 2 in the closed
conformation.132b
Another approach to imaging TGase 2 relies on its targeting by
exogenous agents functionalized with reporter groups. These
agents can be based either on inhibitors or substrates. Regarding
the latter class of imaging probes, cadaverine conjugated to ﬂuo-
rescein isothiocyanate (FITC) was used to detect transglutaminase
activity in living cells.133 Geel et al. visualized the TGase 2 activity
in Movas smooth muscle cells by incubation with pent-4-ynoyl-
cadaverine (Fig. 5, compound 9) followed by ﬂuorescent labeling
with a commercially available Alexa555-azide probe via cop-
per(I)-catalyzed azide–alkyne cycloaddition (CuAAC) and micro-
scopic image analysis.134The dansylated irreversible inhibitor 10 (Fig. 5) bearing a 3-bro-
modihydroisoxazole moiety was used to visualize TGase 2 in HCT-
116 cells by two-photon confocal microscopy, revealing its pres-
ence on the surface and in minor quantities in cytosolic gran-
ules.82a Inhibitors of the same chemotype have been alkyne-
functionalized (Fig. 5, compound 11) to allow microscopic imaging
of the TGase 2 activity in WI-38 ﬁbroblast cultures.82c Fluorescence
labeling after inhibitor targeting was achieved via CuAAC with azi-
dopropylbiotinamide and incubation with streptavidin-conjugated
Alexa555. This assay gave high signals with compound 11, but no
image signal was detected with the less potent epimeric analog
of 11 exhibiting an inverted conﬁguration of the dihydroisoxazole
ring. The rhodamine-labeled peptidic acrylamide inhibitor 12
(Fig. 5) synthesized by Chabot et al. was used for microscopic
detection of TGase 2 in aortic tissue slides from hypertensive rats
treated with warfarin and vitamin K over four weeks. The ﬂuores-
cence signal within the slides increased over time accompanied by
relocation from the media to the adventitia, suggesting the en-
zyme’s involvement in processes of ﬁbrosis.127e
To the best of our knowledge, data on imaging and functional
characterization of TGase 2 via single-photon emission computed
tomography (SPECT) and positron emission tomography (PET)
using radiolabeled probes in vivo are not available to date. How-
ever, the radiosynthesis of a ﬂuorine-18 labeled peptidic diazom-
ethyl ketone-based TGase 2 inhibitor 13 (Fig. 5) has been
disclosed in a conference abstract.135 Preliminary results from
studies of our own institute toward 18F-ﬂuorbenzoylated diamines
and spermine as substrate-based PET tracers have been published
as conference abstracts and in annual proceedings.136
M. Pietsch et al. / Bioorg. Med. Chem. Lett. 23 (2013) 6528–6543 6541Summary: Within this digest Letter we introduced the reader to
the physiological functions and pathological implications of TGase
2, emphasizing its role in tumor progression and biomaterial-tissue
interactions. While results from recent research shed light into the
enzyme’s involvement in human disorders, some of its particular
roles remain enigmatic, especially with regards to the different
conformational and activity states of TGase 2. A survey of current
methods to assay TGase transamidase activities was given. This
will stimulate further medicinal chemistry efforts dealing with
the development of inhibitors and imaging agents targeting TGase
2. Recent results in this ﬁeld were also covered in the Letter.
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